CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
(PK) similarity and efficacy, safety, and immunogenicity of ABP 206 compared with OPDIVO® (nivolumab) in subjects with resected advanced melanoma...
Phase 3
Seoul, Seoul Teugbyeolsi [Seoul-T'ukp, Korea, Republic of and 112 other locations
safety, pharmacokinetics, and preliminary efficacy of the investigational drug PLX3397 in subjects with unresectable or metastatic KIT-mutated melanoma...
Seoul, Korea, Republic of and 4 other locations
This study observes the antitumor activity, safety, tolerability, PK, and pharmacodynamics in patients with inoperable and/or metastatic melanoma...
Phase 2
Seoul, Seodaemun-Gu, Korea, Republic of and 43 other locations
of ceralasertib, when administered as monotherapy and in combination with durvalumab in participants with unresectable or advanced melanoma ...
Phase 2
Seoul, Korea, Republic of and 65 other locations
combined with nivolumab in patients with unresectable or metastatic melanoma. A separate open-label cohort of adults with new, progressive b...
Phase 3
Seoul, Gyeonggi, Korea, Republic of and 138 other locations
The purpose of this study is to determine whether nivolumab is better than ipilimumab to prevent recurrence of melanoma....
Phase 3
Seoul, Korea, Republic of and 135 other locations
belvarafenib as a single agent and in combination with either cobimetinib or cobimetinib plus nivolumab in patients with NRAS-mutant advanced melanoma...
Phase 1
Seoul, Korea, Republic of and 22 other locations
to pembrolizumab with respect to RFS as assessed by the investigator in participants with high-risk resected Stage IIB, IIC, III and IV melanoma...
Phase 3
Seoul, Korea, Republic of and 204 other locations
in patients with locally advanced unresectable or metastatic melanoma with BRAF V600 mutation. A total of approximately 900 patients will be...
Phase 3
Seoul, Korea, Republic of and 396 other locations
is safe and prevents cancer from returning in people with high-risk melanoma. Researchers want to know if V940 with pembrolizumab is better ...
Phase 3
Seoul, Korea, Republic of and 161 other locations
Clinical trials
Research sites
Resources
Legal